Related Experiment Video
Updated: Nov 16, 2025
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
10.1K
Molecular Modeling Studies on Cytochrome P450-mediated Drug Metabolism
Ramesh Muthusamy1, Prasad V Bharatam1
1Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Sector-67, S.A.S. Nagar (Mohali)-160 062, India.
Current Drug Metabolism
|February 19, 2021
Summary
Optimizing drug metabolism is crucial for therapeutic success. Molecular modeling aids in predicting and improving drug metabolic profiles early in development, reducing candidate failure and toxicity risks.
Area of Science:
- Pharmacology
- Computational Chemistry
- Drug Discovery
Background:
- Drug metabolism significantly impacts therapeutic efficacy and safety.
- Poor metabolic profiles lead to candidate attrition and market withdrawal.
- Early optimization of metabolic properties is essential in drug development.
Purpose of the Study:
- To review the current research on drug metabolism using molecular modeling.
- To analyze the role of various computational methods in predicting metabolic profiles.
- To provide insights into cytochrome P450-mediated drug metabolism.
Main Methods:
- Literature review of molecular modeling techniques in drug metabolism.
- Analysis of pharmacophore-based modeling, QSAR, molecular docking, and virtual screening.
- Examination of quantum chemical analysis and molecular dynamics simulations.
Main Results:
- Molecular modeling effectively identifies and optimizes metabolic profiles.
- Computational methods predict substrate specificity, metabolic activity, and potential metabolites.
- Insights into cytochrome P450 interactions and toxicity are provided.
Conclusions:
- Molecular modeling is a valuable tool for enhancing drug metabolic profiles.
- Early computational prediction can mitigate risks associated with poor metabolism.
- This approach facilitates the design of safer and more effective drug candidates.
Keywords:
Drug metabolismcytochrome P450cytochromesmetabolic profilesmolecular modelingtherapeutic targets.More Related Videos
Related Concept Videos
01:17Drug Metabolism: Phase I Reactions
4.2K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
4.2K
01:21Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
579
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in...
The drug's acidity or basicity is essential in...
579
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
149
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
149
01:16Protein-Drug Binding: Mechanism and Kinetics
1.4K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
1.4K
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
75
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
75
01:14Drug Metabolism: Phase II Reactions
4.6K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.6K